Global Liquid Biopsy Market 2017–2023
- December, 2017
- Domain: Healthcare - Diagnostics
Pages:
120
Tables:
14
Charts:
36
Regions/Countries:
4/0
Companies:
20
Enquiry Hours:
10
- Get Free 10% Customization in this Report
Overview:
Liquid biopsy is a minimally or non-invasive technology that detects molecular biomarkers using liquid sample without the need for costly or invasive procedures. These tests have considerable potential for early detection of cancer, treatment and recurrence monitoring, detection of genetic abnormalities in fetus, and graft rejection in transplantation patients. According to the estimation of National Cancer Institute, in the US around 1.6 million new cases of cancer are diagnosed, and 595,690 people have died due to cancer in 2016. According to the Canadian Cancer Society, 202,400 new cases of cancer and nearly 78,000 deaths are estimated in 2016. While in Europe 1.3 million people were diagnosed in 2015. Further, according to the study of World Health Organization, approximately 14 million new cancer cases were diagnosed and is expected to grow by about 70% over the next 2 decades.
The liquid biopsy market is booming due to the rising prevalence of cancer globally, advanced maternal age leading to growing chromosomal aberrations, and the increasing preference of non-invasive liquid biopsy tests over invasive tissue biopsy. The lack of sensitivity and specificity of liquid biopsy tests, high cost of the test with fewer reimbursement facilities, and the lack of trained professionals are some of the factors hampering the market growth. The markets in emerging countries are expected to grow at a rapid pace during the forecast period due to the increasing disease prevalence, healthcare awareness, and healthcare spending.
Market Analysis:
The Global Liquid Biopsy Market is estimated to witness a CAGR of 24.1% during the forecast period 2017–2023. The market is analyzed based on three segments, namely biomarker type, sample type, application, end-users, and regions.
Regional Analysis:
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the liquid biopsy market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions.
Biomarker Type Analysis:
The global liquid biopsy market by biomarker type is segmented into circulating tumor cell (CTC), cell-free DNA (cfDNA), extracellular vesicles, and others. Cell-free DNA (cfDNA) segment is the largest segment in 2016 due to its wide range of application in prenatal testing, transplantation diagnostics, and oncology.
Sample Type Analysis:
The global liquid biopsy market by sample type is segmented into blood and others. Blood sample occupies the major market share in 2016 since most of the tests currently available in the market are blood-based tests.
Application Analysis:
The global liquid biopsy market by application is segmented into cancer and non-cancer applications. Cancer segment occupies the largest market share and is expected to be the fastest growing segment during the forecasted period. Cancer application is further segmented by cancer indication and clinical application.
End-users Analysis:
The global liquid biopsy market by end-users is segmented into hospital and reference laboratories, academic and research institutes, and others. Hospital and reference laboratories occupied a major share of liquid biopsy market in 2016 due to the increasing volume of test samples outsourced to this segment.
Key Players:
Biocept, Inc, F- Hoffmann-la Roche, Illumina, Inc, Natera Inc, Trovagene Inc., Qiagen N.V., Laboratory Corporation of America Holdings, Beijing Genomics Institute, Guardant Health, Inc., Genomic Health, MDx Health SA, Guardant Health, Inc., Myriad Genetics, Inc., and other predominate & niche players.
Competitive Analysis:
Currently, cancer tests dominate the global liquid biopsy market. A lot of new players are concentrating on this market to provide ground-breaking test with high sensitivity, specificity, and less turnaround time. Major market players are acquiring small companies to enhance their product portfolio and strengthen their leadership position in the market. Apart from this, the major players are launching innovative tests to have an upper hand in the market. For instance, in September 2017, Biocept launched Liquid Biopsy test for NRAS mutations.
Benefits:
The report provides complete details about the usage and adoption rate of liquid biopsy tests in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the test adoption in the upcoming years along with the details of commercial tests available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding their business in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Total addressable market
1.3 Industry Trends
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Importance of Liquid biopsy
3.3 Complications of Liquid biopsy
3.4 Segmented Addressable Market (SAM)
3.5 Industry Trends
3.6 Related Markets
3.6.1 Cell-free DNA testing market
3.6.2 Transplantation Diagnostics Market
3.6.3 Point Of Care Diagnostics Market
4 Market Outlook
4.1 Overview
4.2 Regulatory framework
4.3 Funding scenario
4.4 Market segmentation
4.5 PEST Analysis
4.6 Porter 5(Five) Forces
5 Market Characteristics
5.1 DRO – Global Liquid Biopsy Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising Prevalence of Cancer globally
5.1.1.2 Growing preference of non-invasive liquid biopsy tests over invasive tissue biopsy
5.1.1.3 Advanced maternal age leads to growing incidence of babies with chromosomal aberrations
5.1.1.4 Growing emphasis on personalized medicine
5.1.2 Opportunities
5.1.2.1 Upsurge in healthcare spending and growing healthcare awareness in emerging countries
5.1.2.2 Advantages of exosomes as source materials
5.1.2.3 Agreements and collaborations
5.1.3 Restraints
5.1.3.1 Lack of specificity and sensitivity of liquid biopsy tests
5.1.3.2 High charge of the test with less reimbursement facilities
6 Biomarker Types: Market Size and Analysis
6.1 Overview
6.2 Circulating tumor cell (CTC)
6.3 Cell-free DNA (cfDNA)
6.4 Extracellular vesicles
6.5 Others
7 Application: Market Size and Analysis
7.1 Overview
7.2 Cancer application
7.2.1 Cancer application, By cancer type
7.2.1.1 Lung cancer
7.2.1.2 Breast cancer
7.2.1.3 Colorectal cancer
7.2.1.4 Prostate cancer
7.2.1.5 Melanoma
7.2.1.6 Others
7.2.2 Cancer application, By clinical application
7.3 Non-Cancer application
7.3.1 Prenatal testing
7.3.2 Transplantation diagnsotics
8 Sample type: Market Size and Analysis
8.1 Overview
8.2 Blood
8.3 Others
9 End Users: Market Size and Analysis
9.1 Overview
9.2 Hospitals and reference laboratories
9.3 Academic and research Institutes
9.4 Others
10 Regions: Market Size and Analysis
10.1 Overview
10.2 North America
10.2.1 Overview
10.2.2 United states
10.2.3 Canada
10.3 Europe
10.3.1 Overview
10.3.2 United Kingdom
10.3.3 Germany
10.3.4 France
10.3.5 Spain
10.4 APAC
10.4.1 Overview
10.4.2 India
10.4.3 China
10.4.4 Japan
10.5 Rest of the World
10.5.1 Overview
10.5.2 Brazil
10.5.3 Middle East
11 Competitive Landscape
11.1 Overview
12 Vendor Profiles
12.1 Biocept, Inc.,
12.1.1 Overview
12.1.1 Business Focus
12.1.2 SWOT Analysis
12.1.3 Business Strategy
12.2 Natera, Inc.
12.2.1 Overview
12.2.2 Geographic Presence
12.2.3 Business Focus
12.2.4 SWOT Analysis
12.2.5 Business Strategy
12.3 Laboratory Corporation of America Holdings (LABCORP)
12.3.1 Overview
12.3.2 Business Unit
12.3.3 Geographic Presence
12.3.4 Business Focus
12.3.5 SWOT Analysis
12.3.6 Business Strategy
12.4 Illumina, Inc.,
12.4.1 Overview
12.4.2 Geographic Presence
12.4.3 Business Focus
12.4.4 SWOT Analysis
12.4.5 Business Strategy
12.5 Myriad Genetics
12.5.1 Overview
12.5.2 Business Unit
12.5.3 Business Focus
12.5.4 SWOT Analysis
12.5.5 Business Strategy
12.6 F.Hoffmann-La Roche Ltd
12.6.1 Overview
12.6.2 Business Unit
12.6.3 Geographic Presence
12.6.4 Business Focus
12.6.5 SWOT Analysis
12.6.6 Business Strategy
Companies to Watch For
12.7 CareDx, Inc
12.7.1 Overview
12.7.2 caredx: Recent Developments
12.8 Beijing Genomics Institute (BGI)
12.8.1 Overview
12.8.2 Beijing Genomics Institute: Recent Developments
12.9 MDxHealth SA
12.9.1 Overview
12.9.2 MDxHealth: Recent Developments
12.10 Exosome Diagnostics
12.10.1 Overview
12.10.2 Exosome Diagnostics: Recent Developments
12.11 QIAGEN NV
12.11.1 Overview
12.11.2 Qiagen NV: Recent Developments
12.12 Agena Bioscience
12.12.1 Overview
12.12.2 Agena Bioscience: Recent Developments
12.13 LifeCodexx AG
12.13.1 Overview
12.13.2 LifeCodexx AG: Recent Developments
12.14 Quest Diagnostics
12.14.1 Overview
12.14.2 Quest Diagnostics: Recent Developments
12.15 Guardant Health
12.15.1 Overview
12.15.2 Guardant Health: Recent Developments
12.16 Angle plc
12.16.1 Overview
12.16.2 Angle PLC: Recent Developments
12.17 Menarini-silicon Biosystems
12.17.1 Overview
12.17.2 Menarini-Silicon Biosystems: Recent Developments
12.18 Inivata Limited
12.18.1 Overview
12.18.2 Inivata Limited: Recent Developments
12.19 Personal Genome Diagnostics
12.19.1 Overview
12.19.2 Personal Genome Diagnostics: Recent Developments
12.20 Trovagene
12.20.1 Overview
12.20.2 Trovagene, Inc.: Recent Developments
Annexure
Abbreviations
TABLE 1 FUNDING SCENARIO 18
TABLE 2 GLOBAL CELL-FREE DNA TESTING MARKET BY TEST TYPES, 2016–2023 ($MILLION) 30
TABLE 3 GLOBAL CELL-FREE DNA TESTING MARKET BY APPLICATION, 2016–2023 ($MILLION) 34
TABLE 4 GLOBAL CELL-FREE DNA TESTING MARKET REVENUE BY REGIONS, 2016–2023 ($MILLION) 38
TABLE 5 GLOBAL NON-INVASIVE PRENATAL TESTING MARKET BY VENDOR RANKING, 2016 47
TABLE 6 OTHER PROMINENT VENDORS OF CELL-FREE DNA TESTING MARKET 48
TABLE 7 CAREDX, INC.: SNAPSHOT 79
TABLE 8 LIFECODEXX AG.: SNAPSHOT 81
TABLE 9 BIOCEPT, INC.: SNAPSHOT 83
TABLE 10 QUEST DIAGNOSTICS: SNAPSHOT 85
TABLE 11 GUARDANT HEALTH INC.: SNAPSHOT 88
TABLE 12 INIVATA LIMITED: SNAPSHOT 90
TABLE 13 PERSONAL GENOME DIAGNOSTICS: SNAPSHOT 91
TABLE 14 TROVAGENE, INC.: SNAPSHOT 93
Research Framework
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
- Forecasting
Market related information is congregated from both primary and secondary sources.
Primary sources
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Secondary sources
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.
